Literature DB >> 19017743

TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness.

Eric Chastre1, Mahmoud Abdessamad, Alexey Kruglov, Erik Bruyneel, Marc Bracke, Yolande Di Gioia, Mary C Beckerle, Frans van Roy, Larissa Kotelevets.   

Abstract

We recently established the critical role of the PTEN/MAGI-1b signalosome in stabilization of cell-cell contacts and suppression of invasiveness. The PTEN tumor suppressor is recruited to E-cadherin junctional complexes through the binding to the second PDZ domain of the MAGI-1b scaffolding molecule, whereas beta-catenin interacts with the fifth PDZ domain. To identify additional effectors of this signalosome, we used yeast 2-hybrid screening. Among the clones identified, we focused on TRIP6, which belongs to the zyxin family of proteins. We demonstrated that TRIP6 interacted directly with MAGI-1b by binding to its fifth PDZ domain. Ectopic expression of TRIP6 induced invasiveness in the epithelial MDCK and MDCKts-src cells in a PI3-kinase- and a NF-kappaB-dependent manner and impaired cell-cell aggregation at least in part by uncoupling adherens junctional complexes from the cytoskeleton. The TRIP6Stop473 mutant, which lacks the PDZ binding motif, was still able to increase NF-kappaB and Akt activities but did not promote invasiveness or interfere with cell-cell aggregation. Intracellular delivery of competing peptides corresponding to TRIP6 or beta-catenin C terminus restored invasive properties in MDCKts-src TRIP6Stop473 cells, highlighting the requirement of PDZ scaffolds in junctional complexes activity. TRIP6 overexpression in colon tumors suggest its critical role in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017743     DOI: 10.1096/fj.08-106344

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

1.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Authors:  Julien Laffaire; Sibille Everhard; Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Aurelien de Reyniès; Renaud Schiappa; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Joëlle Thillet; François Ducray
Journal:  Neuro Oncol       Date:  2010-10-05       Impact factor: 12.300

2.  Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Authors:  Jessica Amlin-Van Schaick; Sungjin Kim; Karl W Broman; Karlyne M Reilly
Journal:  Mamm Genome       Date:  2011-12-08       Impact factor: 2.957

3.  Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.

Authors:  Xiaobing Miao; Xiaohong Xu; Yaxun Wu; Xinghua Zhu; Xudong Chen; Chunsun Li; Xiaoyun Lu; Yali Chen; Yushan Liu; Jieyu Huang; Yuchan Wang; Song He
Journal:  Tumour Biol       Date:  2015-08-23

4.  The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration.

Authors:  Yun-Ju Lai; Victor T G Lin; Ying Zheng; Etty N Benveniste; Fang-Tsyr Lin
Journal:  Mol Cell Biol       Date:  2010-09-27       Impact factor: 4.272

5.  MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis.

Authors:  Jun-Ichi Abe; Kyung Ae Ko; Sivareddy Kotla; Yin Wang; Jesus Paez-Mayorga; Ik Jae Shin; Masaki Imanishi; Hang Thi Vu; Yunting Tao; Miguel M Leiva-Juarez; Tamlyn N Thomas; Jan L Medina; Jong Hak Won; Yuka Fujii; Carolyn J Giancursio; Elena McBeath; Ji-Hyun Shin; Liliana Guzman; Rei J Abe; Jack Taunton; Naoki Mochizuki; William Faubion; John P Cooke; Keigi Fujiwara; Scott E Evans; Nhat-Tu Le
Journal:  JCI Insight       Date:  2019-04-04

6.  TRIP6 inhibits Hippo signaling in response to tension at adherens junctions.

Authors:  Shubham Dutta; Sebastian Mana-Capelli; Murugan Paramasivam; Ishani Dasgupta; Heather Cirka; Kris Billiar; Dannel McCollum
Journal:  EMBO Rep       Date:  2017-12-08       Impact factor: 8.807

Review 7.  PTPN13/PTPL1: an important regulator of tumor aggressiveness.

Authors:  Gilles Freiss; Dany Chalbos
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

8.  c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation.

Authors:  Brooke K McMichael; Stephanie M Meyer; Beth S Lee
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

Review 9.  TRIP6: an adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activity.

Authors:  Victor T G Lin; Fang-Tsyr Lin
Journal:  Cell Signal       Date:  2011-06-13       Impact factor: 4.315

10.  Characterization of TRIP6-dependent nasopharyngeal cancer cell migration.

Authors:  Jie Fei; Jihong Li; Sunan Shen; Weidong Zhou
Journal:  Tumour Biol       Date:  2013-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.